A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
ERX Pharmaceuticals
Study ID
NCT07570758
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Obesity & Overweight

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • ERX1000 — DRUG
    2mg tablet administered orally twice weekly.
  • Placebo — OTHER
    2mg Placebo tablet identical in appearance to 2mg ERX1000 tablet

Study Details

The primary objective is to assess the safety and tolerability of oral dose ERX1000 in obese subjects.

Key Dates

Start date
May 28, 2026
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Treatment Arm
    This arm will receive oral doses of ERX1000.
  • Placebo Comparator: Placebo Arm
    This arm will receive placebo doses.

Primary Outcome Measure

Change in Body Weight of Participants from Baseline to Weeks 12 and 24 [ Time Frame: From enrollment to the end of treatment at Week 24. ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Monroe Biomedical ResearchLouisvilleKentucky40213
Harold Bays, MD (PRINCIPAL_INVESTIGATOR)
Monroe Biomedical ResearchMonroeNorth Carolina28112
Awawu Igbinadolor, MD (PRINCIPAL_INVESTIGATOR)
Monroe Biomedical ResearchNorth CharlestonSouth Carolina29406
Gregory J Feldman, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Louisville, KY

By research site
Monroe Biomedical Research· Louisville, KYMonroe Biomedical Research· Monroe, NCMonroe Biomedical Research· North Charleston, SC

Related Studies